CD38–RyR2 axis–mediated signaling impedes CD8 ⁺ T cell response to anti-PD1 therapy in cancer

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy2024 · 5 citations
2. 2High CD38 expression defines a mitochondrial function adapted CD8 + T cell subset with implications for lung cancer immunotherapy2024
3. 3Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responsesOriginal Research · 2022 · 373 citations
4. 4Differential signaling through the PD-1 receptor allows for a distinct inhibitory signature and unique signal dichotomy between PD-L1 and PD-L2 2261044Original Research · 2026
5. 5PD-1 protects expanding human T cells from premature restimulation-induced cell death by modulating TCR and CD28 signalingOriginal Research · 2026 · 5 citations